Fitusiran Approved for Hemophilia A, B

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without inhibitors. Fitusiran is a first-in-class small interfering RNA therapeutic that reduces antithrombin production in the liver by downgrading antithrombin gene expression. Antithrombin is a protein that inhibits clot formation. …